When the central nervous system (CNS) is injured—whether by a sudden stroke or the slow grind of neurodegeneration—the brain’s failure to repair itself is often framed as a lack of regenerative "fuel." However, a growing body of evidence suggests the problem is not just a lack of growth, but the presence of active "molecular brakes." Following an insult, the microenvironment shifts from supportive to hostile, deploying a suite of physical and chemical barriers that actively suppress the brain's latent ability to reorganize and heal.
The Glial Scar as a Physical and Chemical Barrier
The most visible manifestation of this inhibitory environment is the glial scar. Traditionally viewed as a passive structural patch, researchers like Shuangqin Chen and Zijian Xiao have shown that the scar is a complex biochemical wall. In Therapeutic strategies for brachial plexus injury, they describe how reactive astrocytes and microglia create a barrier that prevents regrowing axons from re-entering the nervous system.
This process is driven by blood-borne factors that leak into the brain during injury. Han Zhang and colleagues found that the clotting enzyme thrombin acts as a molecular switch via the PAR1 receptor, forcing astrocytes to multiply in place rather than migrate, effectively "locking" the scar into a dense, impenetrable mass [Thrombin induces morphological and inflammatory astrocytic responses via activation of PAR1 receptor].
The MAO-B–GABA Axis: A Chemical Brake
Beyond the physical scar, a more subtle chemical suppression occurs: tonic inhibition. While neurons typically communicate via rapid "phasic" pulses of neurotransmitters, astrocytes can release a steady background leak of Gamma-amino butyric acid (GABA).
Bo-Eun Yoon has demonstrated that in diseased states, astrocytes switch to an alternative metabolic pathway. Instead of the standard neuronal method, they use the enzyme Monoamine Oxidase B (MAO-B) to convert the polyamine putrescine into GABA [GABA as a rising gliotransmitter]. This astrocytic GABA is then released through channels like BEST1, as shown by Jinhyeong Joo and Sun Yeong Choi, accounting for the majority of the brain's baseline inhibitory tone [Generation of Astrocyte-specific BEST1 Conditional Knockout Mouse with Reduced Tonic GABA Inhibition in the Brain].
Functional Dormancy and the Suppression of Growth Factors
This chronic GABAergic "noise" does more than just quiet the brain; it actively halts the repair machinery. Jung Moo Lee and Hye Yeong Lee recently identified the MAOB–GABA axis as a direct regulator of Brain-Derived Neurotrophic Factor (BDNF). When GABA levels are high, the signaling pathways for BDNF—the "fertilizer" of the brain—are downregulated, preventing neurons from surviving or regrowing [Astrocytic monoamine oxidase B (MAOB)–gamma-aminobutyric acid (GABA) axis as a molecular brake on repair following spinal cord injury].
This creates a state of functional dormancy. As Min‐Ho Nam argues in his work on Parkinson’s Disease, many neurons in the injured brain are not actually dead; they are simply suppressed by this excessive tonic inhibition [KDS2010, a newly developed reversible MAO-B inhibitor, as an effective therapeutic candidate for Parkinson’s disease].
Reversing the Inhibition
The core insight of this research direction is that by removing these brakes, we can restore function without necessarily needing to replace lost cells. Several "brake-release" strategies are currently being explored:
- MAO-B Inhibition: A novel, reversible inhibitor called KDS2010 has shown the ability to reduce astrocytic GABA, restore BDNF levels, and improve motor recovery in models of spinal cord injury and Parkinson’s [Min‐Ho Nam, Jung Moo Lee].
- Receptor Blockade: Inhibiting the CCR5 receptor—a known negative regulator of plasticity—can facilitate circuit reorganization after stroke [Shi Yin]. Similarly, blocking RGMa (Repulsive Guidance Molecule-a) removes a protein that actively prevents neurite outgrowth [Aijaz Parray].
- Cellular Reprogramming: Instead of fighting the glial scar, researchers like Heeyoung An are using tools like TRANsCre-DIONE to convert the scar-forming astrocytes themselves into functional neurons, effectively turning the "brake" into a "motor" [TRANsCre-DIONE transdifferentiates scar-forming reactive astrocytes into functional motor neurons].
By shifting the focus from simply adding growth factors to actively removing the endogenous inhibitors, this field is uncovering a path toward waking up the dormant potential of the injured nervous system.